December 8, 2025BloodOpen Access

Ex vivo treatment by mitapivat, an allosteric pyruvate kinase activator, reduced oxidative stress to support terminal erythropoiesis of non-transfusion dependent thalassemia patients due to β-thalassemia/hb e disease

View Full Paper

Ask AI

Bookmark

Authors

TSThidarat SuksangplengSiriraj Hospital

Discussion

Member takes

Implication

Ex vivo treatment by mitapivat reduced oxidative stress and improved erythroid cell viability in non-transfusion dependent thalassemia patients, highlighting its clinical relevance.

Key Points

Oxidative stress was significantly reduced in erythroid cells treated with mitapivat during differentiation stages.
The mean hemoglobin concentration was 7.9 ± 1.4 gm/dL in patients with β-thalassemia/Hb E disease.
Erythroid culture systems effectively allowed for proerythroblast differentiation and ATP production evaluation.
Mitapivat treatment suggests clinical benefits for managing oxidative stress in patients with β-thalassemia.

Cite This Study

Thidarat Suksangpleng (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddda https://doi.org/10.1182/blood-2025-2916

View Full Paper

Ask AI

Bookmark

Implication

Ex vivo treatment by mitapivat reduced oxidative stress and improved erythroid cell viability in non-transfusion dependent thalassemia patients, highlighting its clinical relevance.